CD40LG and autoimmune polyendocrinopathy: APS patients were the only group with patients that tested positive for aPS/PT IgG (39.1%) and had significantly higher rates of aPS/PT IgM testing [58.6% vs. 8% (COVID-19) and vs. 25.3% (infections)].